Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021061867 - ANTI-CD47 ANTIBODIES, ACTIVATABLE ANTI-CD47 ANTIBODIES, AND METHODS OF USE THEREOF

Publication Number WO/2021/061867
Publication Date 01.04.2021
International Application No. PCT/US2020/052332
International Filing Date 23.09.2020
IPC
A61K 47/68 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 47/6849
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6849the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
A61K 47/6891
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6891Pre-targeting systems involving an antibody for targeting specific cells
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
Applicants
  • CYTOMX THERAPEUTICS, INC. [US]/[US]
Inventors
  • MEI, Li
  • FLANDEZ, Jeanne Grace
  • DANIEL, Dylan
  • TIPTON, Kimberly Ann
  • HOSTETTER, Daniel Robert
Agents
  • SHIN, Tae Bum
Priority Data
62/904,53423.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-CD47 ANTIBODIES, ACTIVATABLE ANTI-CD47 ANTIBODIES, AND METHODS OF USE THEREOF
(FR) ANTICORPS ANTI-CD47, ANTICORPS ANTI-CD47 ACTIVABLES, ET LEURS MÉTHODES D'UTILISATION
Abstract
(EN)
The invention relates generally to activatable antibodies that bind to CD47 and methods of making and using these activatable antibodies in a variety of therapeutic, prophylactic, and diagnostic contexts. In some embodiments, the CD47 activatable antibodies bind human and cynomolgus monkey CD47.
(FR)
La présente invention concerne d'une manière générale des anticorps activables se liant à CD47 et des procédés de fabrication et d'utilisation de ces anticorps activables dans une pluralité de contextes thérapeutiques, prophylactiques et diagnostiques. Selon certains modes de réalisation de la présente invention, les anticorps activables de CD47 se lient à CD47 humain et du macaque crabier.
Latest bibliographic data on file with the International Bureau